New Tips to Incorporate DCT Elements in Your Clinical Trials
In a pivotal webcast hosted by Medable, a panel of distinguished experts, including Pamela Tenaerts (Chief Scientific Officer at...
Mandara III Data: Fasenra Aids EGPA Remission, NEJM Reports
Positive results from the MANDARA Phase III trial for FASENRA® (benralizumab) in patients with eosinophilic granulomatosis with polyangiitis (EGPA)...
Biktarvy by Gilead: FDA Approval for Resistant HIV Cases
Gilead Sciences, Inc. has announced the FDA’s approval of an expanded indication for Biktarvy® to treat people with HIV...
Merck’s Keytruda Gets Positive CHMP Opinion for NSCLC Therapy
Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
Xolair’s NEJM Phase III Data: Hope for Multiple Food Allergies
Genentech announced key findings from Stage 1 of the NIH-sponsored Phase III OUtMATCH study, published in the New England...
Silence Therapeutics Nabs $10M From AstraZeneca Phase 1 Start
Silence Therapeutics plc, a biotechnology company specializing in RNA interference (RNAi) therapies, has announced the initiation of a Phase...
The Enhanced eConsent Evolution: A New Era for Trials
A groundbreaking proof-of-concept study conducted by Medable and the Duke BASE Lab unveiled electronic informed consent (eConsent) solutions in...
Worldwide Clinical Trials Trials Upgrades Unit Pharmacy for Client Efficiency
Worldwide Clinical Trials has enhanced its Clinical Pharmacology Unit (CPU) in San Antonio, Texas, with a significant expansion completed...
2024 SCOPE Summit Insights: Navigating New Clinical Trial Change
The 2024 SCOPE Summit catalyzed thought-provoking dialogue on the transformative currents sweeping through the clinical trials landscape. Hassan Kadhim,...
Tagrisso’s Phase III Success in Unresectable EGFR Lung Cancer
AstraZeneca’s TAGRISSO® (osimertinib) has shown positive results in the LAURA Phase III trial, demonstrating a significant and clinically meaningful...